Following three clinical trials, the FDA has approved a new preventive treatment for neonates, infants, and toddlers that prevents respiratory syncytial virus (RSV) in those age populations.
A multi-institutional retrospective cohort study presented at the American Heart Association Scientific Sessions 2025 found that adults with respiratory syncytial virus infection faced a nearly fourfold...
In this respiratory disease roundup, researchers highlight the efficacy of clesrovimab in preventing respiratory syncytial virus infections in infants, the influenza vaccine's updated formulation this virus...
